Setting 
My Cart

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Toggle Nav
mobile icon
Close
  • Menu
  • Setting

Signaling Pathways

Items 1-10 of 67

Page
per page
  1. Lapatinib Ditosylate
    A3967 Lapatinib Ditosylate
    Target: EGFR|ErbB-2
    Summary: EGFR/HER2 inhibitor,potent and selective
      ≥24.3 mg/mL
  2. Vatalanib
    A3969 Vatalanib
     1 Citation
    Target: VEGFR
    Summary: VEGFR-1/-2 inhibitor,cell-permeable
      ≥16.85 mg/mL
  3. Lapatinib
    A8218 Lapatinib
     2 Citation
    Target: ErbB
    Summary: EGFR/HER2 inhibitor,potent,selective and reversible
      ≥29.05 mg/mL
  4. Gefitinib (ZD1839)
    A8219 Gefitinib (ZD1839)
     3 Citation
    Target: EGFR
    Summary: Selective EGFR inhibitor
      ≥22.34 mg/mL
  5. Nilotinib(AMN-107)
    A8232 Nilotinib(AMN-107)
     1 Citation
    Target: Bcr-Abl
    Summary: Bcr-Abl kinase inhibitor,selective
      ≥26.5 mg/mL
  6. Regorafenib
    A8236 Regorafenib
     4 Citation
    Target: Raf|VEGFR|PDGFR|c-Kit|RET
    Summary: Inhibitor of VEGFR/PDGFR/FGFR/mutant kit/RET/Raf-1
      ≥25.04 mg/mL
  7. PP 1
    A8215 PP 1
    Target: Src|EGFR|JAK|ZAP-70
    Summary: Src family tyrosine kinase inhibitor
  8. Nintedanib (BIBF 1120)
    A8252 Nintedanib (BIBF 1120)
     3 Citation
    Target: VEGFR|PDGFR|FGFR
    Summary: VEGFR/PDGFR/FGFR inhibitor
      insoluble in H2O; insoluble in EtOH; ≥5.34 mg/mL
  9. Bosutinib (SKI-606)
    A2149 Bosutinib (SKI-606)
     1 Citation
    Target: Bcr-Abl|Src
    Summary: Potent Abl/Src kinases
      ≥26.5 mg/mL
  10. PHA-665752
    A2307 PHA-665752
     1 Citation
    Target: c-MET
    Summary: C-Met inhibitor,potent and ATP-competitive

Items 1-10 of 67

Page
per page